Vertex制药公司认为,尽管收入较低,但随着美国银行提高物价目标,股价会上升。 Vertex Pharmaceuticals sees stock rise as Bank of America raises price target despite lower earnings.

Vertex Pharmaceuticals 的股票价格上涨，美国银行将其目标价从 555.00 美元上调至 567.00 美元，并保持强劲的买入评级。 Vertex Pharmaceuticals' stock has seen a boost, with Bank of America raising its price target to $567.00, up from $555.00, and maintaining a strong buy rating. 尽管该公司的每股收益低于预期, 仅为3.54美元, 但该公司以其囊性纤维化治疗而闻名, 市值为1241亿美元, 分析师对其持"适度购买"的看法很好. Despite reporting lower than expected earnings per share of $3.54 for the latest quarter, the company, known for its cystic fibrosis treatments, has a market cap of $124.16 billion and is viewed favorably by analysts with a "Moderate Buy" consensus.